Array BioPharma Inc. (ARRY) and Pierre Fabre announced Monday morning that Part 1 of the Phase 3 study of LGX818 and MEK162 in patients with BRAF-mutant advanced, unresectable or metastatic melanoma met its primary endpoint.
from RTT - Before the Bell http://ift.tt/2cyqzqj
via IFTTT
No comments:
Post a Comment